Knight Therapeutics Inc.

TSX:GUD Stock Report

Market Cap: CA$533.2m

Knight Therapeutics Valuation

Is GUD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GUD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GUD (CA$5.29) is trading below our estimate of fair value (CA$14.68)

Significantly Below Fair Value: GUD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GUD?

Key metric: As GUD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GUD. This is calculated by dividing GUD's market cap by their current revenue.
What is GUD's PS Ratio?
PS Ratio1.5x
SalesCA$348.64m
Market CapCA$533.25m

Price to Sales Ratio vs Peers

How does GUD's PS Ratio compare to its peers?

The above table shows the PS ratio for GUD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.2x
VRNO Verano Holdings
0.6x5.0%CA$722.2m
TSND TerrAscend
0.7x9.9%CA$375.8m
ACB Aurora Cannabis
1.1x11.8%CA$331.8m
CPH Cipher Pharmaceuticals
10.3x18.8%CA$380.3m
GUD Knight Therapeutics
1.5x5.9%CA$533.2m

Price-To-Sales vs Peers: GUD is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (3.2x).

Price to Sales Ratio vs Industry

How does GUD's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

25 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.2x2.6%US$78.97m
TIUM.U Cansortium
0.2xn/aUS$25.68m
ACRG.A.U Acreage Holdings
0.09xn/aUS$20.65m
MRV Nuvo Pharmaceuticals
0.2xn/aUS$11.21m
GUD 1.5xIndustry Avg. 0.8xNo. of Companies25PS012345+
25 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GUD is expensive based on its Price-To-Sales Ratio (1.5x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is GUD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GUD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: GUD is expensive based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GUD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$5.29
CA$7.09
+33.9%
12.9%CA$9.00CA$6.10n/a7
Nov ’25CA$5.65
CA$7.53
+33.3%
9.6%CA$9.00CA$6.75n/a6
Oct ’25CA$5.83
CA$7.60
+30.4%
9.1%CA$9.00CA$6.75n/a7
Sep ’25CA$5.49
CA$7.60
+38.4%
9.1%CA$9.00CA$6.75n/a7
Aug ’25CA$5.67
CA$7.24
+27.7%
9.3%CA$8.00CA$5.75n/a7
Jul ’25CA$5.67
CA$7.24
+27.7%
9.3%CA$8.00CA$5.75n/a7
Jun ’25CA$6.00
CA$7.24
+20.7%
9.3%CA$8.00CA$5.75n/a7
May ’25CA$5.77
CA$6.75
+17.0%
11.3%CA$7.60CA$5.40n/a7
Apr ’25CA$5.32
CA$6.64
+24.8%
12.5%CA$7.60CA$5.25n/a6
Mar ’25CA$5.53
CA$6.48
+17.1%
11.4%CA$7.60CA$5.25n/a6
Feb ’25CA$5.37
CA$6.37
+18.6%
12.0%CA$7.60CA$5.25n/a5
Jan ’25CA$5.19
CA$6.48
+24.8%
11.4%CA$7.60CA$5.25n/a6
Dec ’24CA$5.27
CA$6.48
+22.9%
11.4%CA$7.60CA$5.25n/a6
Nov ’24CA$4.61
CA$6.23
+35.2%
8.2%CA$6.75CA$5.40CA$5.656
Oct ’24CA$4.50
CA$6.20
+37.8%
7.8%CA$6.75CA$5.40CA$5.837
Sep ’24CA$4.58
CA$6.20
+35.4%
7.8%CA$6.75CA$5.40CA$5.497
Aug ’24CA$4.83
CA$6.15
+27.3%
8.9%CA$6.75CA$5.30CA$5.677
Jul ’24CA$4.94
CA$6.15
+24.5%
8.9%CA$6.75CA$5.30CA$5.677
Jun ’24CA$4.91
CA$6.15
+25.3%
8.9%CA$6.75CA$5.30CA$6.007
May ’24CA$4.61
CA$6.15
+33.4%
8.9%CA$6.75CA$5.30CA$5.777
Apr ’24CA$4.40
CA$6.15
+39.8%
8.9%CA$6.75CA$5.30CA$5.327
Mar ’24CA$5.11
CA$7.09
+38.7%
10.6%CA$7.75CA$5.40CA$5.537
Feb ’24CA$5.23
CA$7.09
+35.5%
10.6%CA$7.75CA$5.40CA$5.377
Jan ’24CA$5.18
CA$7.09
+36.8%
10.6%CA$7.75CA$5.40CA$5.197
Dec ’23CA$5.35
CA$7.09
+32.4%
10.6%CA$7.75CA$5.40CA$5.277
Nov ’23CA$5.53
CA$7.12
+28.8%
10.9%CA$7.80CA$5.40CA$4.617

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Fennec Pharmaceuticals

US$129.5m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

7D

30.1%

1Y

-38.9%

Verano Holdings

CA$765.1m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

7D

-14.8%

1Y

-65.2%

Decibel Cannabis

CA$28.8m

An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.

DB

CA$0.065

7D

0%

1Y

-53.6%